Literature DB >> 11344385

Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia.

B H McCarberg1, R L Barkin.   

Abstract

Effective management of chronic pain has become an increasingly critical issue in health care. Opioid agonists are among the most effective analgesics available for reducing pain perception; however, their chronic use is controversial. This is primarily due to regulatory barriers, misunderstandings about pain management among primary caregivers, fear of adverse side effects, and misconceptions about the potential risks of addiction. Short-acting opioids provide effective analgesia for acute pain but should be avoided as primary analgesics for chronic pain management. Long-acting opioids have greater utility than short-acting opioids in treating chronic pain in patients with consistent pain levels. Results of studies show that improved quality of life is directly related to the use of long-acting opioids in patients with chronic pain of both cancer and noncancer etiology. Short-acting opioids may be used during the initial dose titration period of long-acting formulations and as rescue medication for episodes of breakthrough pain. Clinical experience reveals that selection of an effective pain regimen for the patient with chronic pain, combined with aggressive management of side effects, leads to improved overall functioning and quality of life.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11344385     DOI: 10.1097/00045391-200105000-00006

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  37 in total

1.  The enigma of morphine tolerance: recent insights.

Authors:  S B Ray; S Wadhwa
Journal:  J Biosci       Date:  2001-12       Impact factor: 1.826

2.  Chronic pain and narcotics: a dilemma for primary care.

Authors:  Yngvild Olsen; Gail L Daumit
Journal:  J Gen Intern Med       Date:  2002-03       Impact factor: 5.128

3.  Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects.

Authors:  Mona Darwish; Mary Bond; William Tracewell; Philmore Robertson; Ronghua Yang
Journal:  Clin Drug Investig       Date:  2015-01       Impact factor: 2.859

Review 4.  Five pitfalls in decisions about diagnosis and prescribing.

Authors:  Jill G Klein
Journal:  BMJ       Date:  2005-04-02

5.  A prospective, open-label, multicenter study of the clinical efficacy of extended-release hydromorphone in treating cancer pain inadequately controlled by other analgesics.

Authors:  Hye-Suk Han; Ki Hyeong Lee; Kyung Hee Lee; Jeong Seon Ryu; Young Chul Kim; Seung Woo Park; Ho-Suk Oh; Kyung Tae Park; Jung Hye Kwon; Pyung Bok Lee; Won Sik Lee; Yang Soo Kim; Joong Bae Ahn; Seong Woo Jeon; Sung Yong Lee; Young Mi Seol; Jung Hun Kang; Young Jin Yuh; So Yeon Oh; Suk Ran Kim; Jin Seok Ahn
Journal:  Support Care Cancer       Date:  2013-11-08       Impact factor: 3.603

Review 6.  Opioids for managing chronic non-malignant pain: safe and effective prescribing.

Authors:  Meldon Kahan; Anita Srivastava; Lynn Wilson; Angela Mailis-Gagnon; Deana Midmer
Journal:  Can Fam Physician       Date:  2006-09       Impact factor: 3.275

Review 7.  A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs.

Authors:  Charles E Argoff; Daniel I Silvershein
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

8.  Dose proportionality of a hydrocodone extended-release tablet formulated with abuse-deterrence technology.

Authors:  Mona Darwish; Ronghua Yang; William Tracewell; Philmore Robertson; Mary Bond
Journal:  Clin Drug Investig       Date:  2015-05       Impact factor: 2.859

9.  An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain.

Authors:  Magdi Hanna; Alberto Tuca; John Thipphawong
Journal:  BMC Palliat Care       Date:  2009-09-15       Impact factor: 3.234

10.  Effect of long-term treatment of morphine on enzymes, oxidative stress indices and antioxidant status in male rat liver.

Authors:  Saeed Samarghandian; Reza Afshari; Tahereh Farkhondeh
Journal:  Int J Clin Exp Med       Date:  2014-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.